EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Licit use of illicit drugs for treating depression: the pill and the process

Alejandro Torrado Pacheco, Bita Moghaddam

Journal of Clinical Investigation · 2024

DOI: 10.1172/jci180217 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, 2024. Verfasst von Alejandro Torrado Pacheco und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Behavioral Neuroscience, and. Hauptthemen laut MEDLINE: Ketamine, Depression, Illicit Drugs. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiatric disorders. All clinical data collected so far with regard to psilocybin or MDMA, which have reported positive outcomes for treating depression, anxiety, posttraumatic stress disorder, and drug or alcohol use disorders, have involved clinician-assisted intervention. While the case for ketamine is assumed to be different, the first report of the successful use of ketamine in psychiatry for treating depression was in combination with psychotherapy, and an emerging literature suggests that the subjective state of individual experiences with ketamine predicts clinical outcome. This Review will focus on (a) a brief review of the literature, showing that the context or the process of drug administration has been an integrative component of published work; (b) the importance of clinical trials to compare the efficacy of the drug ("pill") as a stand-alone treatment versus drug in combination with clinician-assisted psychological support ("process"); and (c) suggestions for future approaches in animal models that take into account the role of systems and behavioral neuroscience in explaining a potential role for context, experience, and expectancy in drug effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetamineDepressionIllicit DrugsHumansAnimalsPsilocybinN-Methyl-3,4-methylenedioxyamphetamine

Substanzen

KetaminePsilocybinIllicit DrugsN-Methyl-3,4-methylenedioxyamphetamine

Autor:innen und Institutionen

  • Department of Behavioral Neuroscience, and.
  • Department of Psychiatry, Oregon Health & Science University, Portland, Oregon, USA.

Förderung

  • NIMH NIH HHS

Zitieren

APA

Torrado Pacheco, A., & Moghaddam, B. (2024). Licit use of illicit drugs for treating depression: the pill and the process. Journal of Clinical Investigation. https://doi.org/10.1172/jci180217

Vancouver

Torrado Pacheco A, Moghaddam B. Licit use of illicit drugs for treating depression: the pill and the process. Journal of Clinical Investigation. 2024. doi:10.1172/jci180217

BibTeX
@article{TorradoPacheco2024,
  author = {Torrado Pacheco, Alejandro and Moghaddam, Bita},
  title = {Licit use of illicit drugs for treating depression: the pill and the process},
  journal = {Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1172/jci180217}
}
Kostenlos starten →